Beta Drugs LimitedQ2 FY27 Results & Financial Update
Beta Drugs Limited: Q2 FY27 consolidated results and company financials – revenue ₹137.49 Cr, PAT ₹19.28 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Beta Drugs price & chart
Market price₹1,971.00
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Beta Drugs Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Beta Drugs Limited reported consolidated revenue from operations of INR 137.49 crore for the quarter ended September 30, 2026, representing a sequential increase of 9.51% compared to INR 125.55 crore in the preceding quarter ended June 30, 2026. Total income for the quarter reached INR 139.24 crore.
Profitability expanded during the second quarter, with profit before tax (PBT) rising by 16.95% sequentially to INR 25.78 crore from INR 22.04 crore in Q1 FY27. Profit after tax (PAT) after non-controlling interests reached INR 19.28 crore, reflecting a 16.98% increase over the previous quarter's PAT of INR 16.49 crore.
Basic and diluted earnings per share (EPS) for Q2 FY27 stood at INR 16.59, compared with INR 14.78 reported in Q1 FY27. Total comprehensive income for the quarter matched the profit after tax at INR 19.28 crore.
Operating performance during the period was shaped by diverse segment trends. While the branded oncology segment experienced temporary moderation due to a scheduled production shutdown for debottlenecking and capacity expansion at the Adley Formulation Plant alongside platinum API supply constraints, orders successfully shifted into the second half of the fiscal year.
Conversely, growth during the quarter was bolstered by robust momentum in contract manufacturing operations (CMO), a 95% rebound in the exports segment during Q2 FY27, and continued strength in the Nivian IVF business following deeper penetration into organized fertility chains.
Total expenses for the quarter stood at INR 113.45 crore, which included cost of materials consumed of INR 61.82 crore, employee benefit expenses of INR 20.45 crore, finance costs of INR 1.64 crore, and depreciation and amortization charges of INR 4.61 crore.
Revenue from operations increased 9.5% sequentially.
01 · Business model
What does Beta Drugs do?
Beta Drugs Limited operates as a specialized pharmaceutical company with a primary emphasis on oncology and assisted reproduction (IVF) therapeutics. The company researches, develops, manufactures, and markets high-end formulations and Active Pharmaceutical Ingredients (APIs).
Commercial operations are anchored by manufacturing infrastructure centered in Baddi, Himachal Pradesh, encompassing facilities such as the Adley Formulation Plant. Its subsidiary network includes Adley Formulations Private Limited, Adley Lab Limited, Beta Research Private Limited, and Nivian Lifesciences Private Limited.
The revenue model spans branded oncology products, Contract Manufacturing Operations (CMO), export dossiers to international markets across Latin America, the Middle East, and Asia-Pacific, as well as dermatology and specialized IVF segments under Nivian.
Strategic execution focuses on strengthening backward integration via captive API manufacturing, maintaining robust research and development pipelines for novel drug delivery systems (NDDS), and expanding international product registrations.
02 · Historical context
What shaped the business before this quarter
The company previously established manufacturing capacities at Baddi, Himachal Pradesh, laying the foundation for subsequent backward integration into API production and specialized oncology formulations.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹137.49 Cr | ₹125.55 Cr |
| Total income | ₹139.24 Cr | ₹127.13 Cr |
| Profit before tax | ₹25.78 Cr | ₹22.04 Cr |
| Profit after tax | ₹19.28 Cr | ₹16.49 Cr |
| EPS | ₹16.59 | ₹14.78 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Growth was substantially led by a 21% rise in Contract Manufacturing Operations, driven by new customer additions and the inclusion of novel products developed by Beta and offered to both new and existing clients.
The exports segment rebounded strongly in Q2 FY27, delivering 95% growth for the quarter, supported by 58 new dossier filings across select markets in Latin America, the Middle East, and Asia-Pacific during the first half of FY27.
The branded oncology segment grew by 17% in H1 FY27 despite temporary production constraints from plant debottlenecking, with management noting that delayed orders have transitioned into the second half of the fiscal year.
What drove margins
Cost of materials consumed stood at INR 61.82 crore for the quarter. Management noted that gross margins expanded to 56.21% in H1 FY27 compared to 51.35% in H1 FY26, driven by higher realisations across key business lines.
Ongoing backward integration at the API plant is scheduled to commence commercial production in Q4 FY27, which is expected to reduce import dependency and support long-term margin improvement.
Employee benefit expenses for the quarter were recorded at INR 20.45 crore, while other expenses aggregated to INR 26.08 crore, reflecting operational scaling across manufacturing and R&D functions.
05 · Demand, customers & order book
Where demand is coming from
Nivian expanded its market reach into organized IVF chains, with sales to organized chains accounting for approximately 25% of total sales in the segment.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates within a single primary business segment, namely Pharmaceuticals, as disclosed in the financial statements.
Nivian delivered an exceptional performance in H1 FY27 with a pro-forma growth of 75%, aided by deeper prescriber penetration, brand building among doctors, and entry into marquee IVF chains as a key supplier.
Geography and market mix
International expansion continued through dossier filings across regulated and semi-regulated markets in Latin America (LATAM), the Middle East and North Africa (MENA), and Asia-Pacific (APAC), bringing total export registrations to 415.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Backward integration at the API plant is progressing toward scheduled commercial production in Q4 FY27, intended to strengthen DMF production for regulated markets.
Projects, capex and execution
Capital expenditure during H1 FY27 included tangible and intangible asset purchases of INR 22.63 crore as part of ongoing facility enhancements and capacity building.
08 · Strategy & new businesses
How the company is trying to change its growth mix
In the dermatology division, Beta signed an exclusive licensing agreement with Frezyderm for the Indian market to distribute high-end cosmeceutical products.
The company launched 4 new products in branded oncology during H1 FY27—comprising 1 novel drug delivery system (NDDS) and 3 new formulations—and maintains a pipeline of over 15 products under development for launch over the next two years.
09 · Reported developments
What changed operationally
Statutory auditors Khurana Sharma & Company issued an unmodified review report on both the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026.
Management evaluated recent National Pharmaceutical Pricing Authority (NPPA) notifications regarding 30% trade margin capping and concluded that the amendments have no significant bearing on realisations or margins.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash generated from operating activities for the half year ended September 30, 2026, was INR 28.00 crore, reflecting operating profits before working capital changes of INR 49.90 crore offset by a net working capital absorption of INR 21.90 crore.
Net cash used in investing activities was INR 51.54 crore, driven by capital expenditure and investments. Net cash generated from financing activities stood at INR 2.50 crore, leading to a net decrease in cash and cash equivalents of INR 21.04 crore for the half-year period.
Capital allocation & funding
As of September 30, 2026, non-current borrowings stood at INR 27.83 crore, while current borrowings were recorded at INR 20.86 crore, against cash and cash equivalents of INR 103.80 crore and a reported net cash position of INR 55 crore.
11 · Management guidance & targets
What management is targeting from here
Management stated expectations to close FY27 at over INR 535 crore in revenue, with EBITDA margins targeted between 23% and 24%, supported by a stronger second half.
Management expects branded oncology to achieve medium-term growth of 20% to 22% with FY27 closing near INR 150 crore, export growth at 30%, Nivian growth exceeding 50%, and dermatology growth at 20%.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Management Certification
The Managing Director and Chief Financial Officer provided formal certification pursuant to Regulation 33(2)(a) of SEBI (LODR) Regulations, 2015, confirming that the financial results do not contain any false or misleading statements.
13 · Previous-quarter changes
What changed since the previous quarter
Consolidated revenue from operations increased by 9.51% sequentially from INR 125.55 crore in Q1 FY27 to INR 137.49 crore in Q2 FY27.
Profit after tax increased by 16.98% sequentially from INR 16.49 crore in Q1 FY27 to INR 19.28 crore in Q2 FY27.
14 · Key Q&A
The quarter, answered directly
What does Beta Drugs do?
Beta Drugs Limited operates as a specialized pharmaceutical company with a primary emphasis on oncology and assisted reproduction (IVF) therapeutics. The company researches, develops, manufactures, and markets high-end formulations and Active Pharmaceutical Ingredients (APIs).
What is the clearest takeaway from Q2 FY27?
Beta Drugs Limited reported consolidated revenue from operations of INR 137.49 crore for the quarter ended September 30, 2026, representing a sequential increase of 9.51% compared to INR 125.55 crore in the preceding quarter ended June 30, 2026. Total income for the quarter reached INR 139.24 crore.
What drove revenue or demand?
Growth was substantially led by a 21% rise in Contract Manufacturing Operations, driven by new customer additions and the inclusion of novel products developed by Beta and offered to both new and existing clients.
What mattered most for margins or profitability?
Cost of materials consumed stood at INR 61.82 crore for the quarter. Management noted that gross margins expanded to 56.21% in H1 FY27 compared to 51.35% in H1 FY26, driven by higher realisations across key business lines.
What changed operationally beyond the headline numbers?
Backward integration at the API plant is progressing toward scheduled commercial production in Q4 FY27, intended to strengthen DMF production for regulated markets.
What is management guiding or targeting from here?
Management stated expectations to close FY27 at over INR 535 crore in revenue, with EBITDA margins targeted between 23% and 24%, supported by a stronger second half.
15 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
16 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
API Plant Commercialisation: Monitor the scheduled commencement of commercial production at the backend API plant in Q4 FY27 to evaluate the impact on import substitution and gross margins.
- 02
H2FY27 Revenue Realisation: Track delivery against management's annual revenue target of over INR 535 crore and segment-specific growth guidance for branded oncology and exports in the second half of FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.